OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
35
Results
Show all
Save search
Copy query
Show results for
Unknown
(35)
Publication Date
Release Date
2025
(8)
2022
(6)
2024
(5)
2023
(5)
2021
(2)
2017
(2)
2015
(2)
2014
(2)
2020
(1)
2018
(1)
2012
(1)
Previous
page
1 / 4
You're on page
1
page
2
page
3
page
4
Next
page
Sort
by:
Relevance
Page size
10
Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.
Not available
S-EPMC4517051
|
biostudies-literature
Cite
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
Not available
S-EPMC4811023
|
biostudies-literature
Cite
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.
Not available
S-EPMC4672027
|
biostudies-literature
Cite
Phase I Clinical Trial of the Bifunctional EGFR/TGF-β Fusion Protein Ficerafusp Alfa (BCA101) Alone and in Combination with Pembrolizumab for Advanced Solid Tumors.
Not available
S-EPMC12616243
|
biostudies-literature
Cite
First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors.
Not available
S-EPMC9395446
|
biostudies-literature
Cite
Pilot clinical trial of neoadjuvant toll-like receptor 7 agonist (Imiquimod) immunotherapy in early-stage oral squamous cell carcinoma.
Not available
S-EPMC11807971
|
biostudies-literature
Cite
Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.
Not available
S-EPMC5452069
|
biostudies-literature
Cite
Patient perspectives on ipilimumab across the melanoma treatment trajectory.
Not available
S-EPMC5651412
|
biostudies-literature
Cite
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies.
Not available
S-EPMC10761073
|
biostudies-literature
Cite
A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery.
Not available
S-EPMC10204709
|
biostudies-literature
Cite
Previous
page
1 / 4
You're on page
1
page
2
page
3
page
4
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets